Clinical case of successful treatment of granulomatosis with polyangiitis


DOI: https://dx.doi.org/10.18565/nephrology.2024.3.36-43

Frolova N.F., Mutovina Z.Yu., Kobzar M.V., Arbolishvili G.N., Pavlov D.P., Shmeleva D.Yu., Manerov F.F., Lysenko M.A.

1) City Clinical Hospital No. 52, Moscow Health Department, Russia; 2) Russian University of Medicine, Moscow, Russia; 3) Central State Medical Academy, Moscow, Russia; 4) Lomonosov Moscow State University, Moscow, Russia; 5) Pirogov Russian National Research Medical University named after N.I. Russian Ministry of Health, Moscow, Russia
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a systemic autoimmune disease characterized by the development of necrotizing inflammation in small blood vessels with damage to various organs and systems. Glucocorticosteroids (GCS) in combination with rituximab or cyclophosphamide are recommended as a pathogenetic therapy for ANCA vasculitis and help restore kidney function and reduce mortality. However, the use of these drugs is associated with certain side effects, primarily this concerns caution with respect to GCS. In this regard, there is a constant search for drugs that could ensure both the achievement of clinical remission of ANCA vasculitis (as the main goal of therapy) and a reduction in the dose, and, ideally, the cancellation of GCS. Based on the data obtained on the role of the alternative complement pathway in the pathogenesis of ANCA vasculitis, avacopan, C5a receptor inhibitor, was proposed for its treatment. In a clinical trial involving patients with ANCA-associated vasculitis, avacopan was non-inferior in achieving remission at week 26 and superior to the GCS therapy group in achieving sustained remission at week 52. All patients in the study also received cyclophosphamide or rituximab. Avacopan is recommended by KDIGO 2024 for inclusion in the induction phase of therapy to reduce the dose of GCS in patients with ANCA glomerulonephritis. Description of the clinical case. The article presents a case of a patient with granulomatosis with polyangiitis (GPA), who was diagnosed at an advanced stage of the disease, with damage to vital organs and an extremely high risk of death. The severity of the patient's condition required mechanical ventilation with subsequent initiation of venovenous extracorporeal membrane oxygenation (ECMO), as well as renal replacement therapy. Therapy was initiated with a series of plasma exchange sessions, pulse therapy, followed by a transition to oral GCS. Taking into account the severity of glomerulonephritis and infectious complications, the decision of the council was to initiate therapy with avacopan, a drug unregistered in the Russian Federation (in combination with cyclophosphamide and rituximab).
Results. After 8 months from the start of pathogenetic therapy, the patient, who was constantly taking a minimum dose of GCS and avacopan, clinically demonstrated remission of GPA in relation to extrarenal manifestations and partial remission of glomerulonephritis.
Keywords: avacopan, ANCA vasculitis, plasma exchange, extracorporeal membrane oxygenation, glucocorticosteroids, renal replacement therapy, rituximab, cyclophosphamide, rapidly progressive glomerulonephritis
Read entire article

About the Autors

Nadiya F. Frolova – Cand.Sci. (Med.), Deputy Chief Physician for Nephrology, Head of the Interdistrict Nephrology Center, City Clinical Hospital No. 52 of the Moscow Healthcare Department. Address: 3 Pekhotnaya st., Moscow, 123182; Associate Professor at the Nephrology Department, Faculty of Continuous Professional Education, Russian University of Medicine (RosUniMed); e-mail: nadiya.frolova@yandex.ru. ORCID: 0000-0002-6086-5220
Margarita V. Kobzar – Analyst of the Project Office, City Clinical Hospital No. 52 of the Moscow Healthcare Department. Address: 3 Pekhotnaya st., Moscow, 123182;
E-mail: m.v.kobzar@yandex.ru. ORCID: 0009-0004-0236-653X.
Zinaida Yu. Mutovina – Cand.Sci. (Med.), Head of the Rheumatology Department No. 1, City Clinical Hospital No. 52 of the Moscow Healthcare Department.
Address: 3 Pekhotnaya st., Moscow, 123182; Associate Professor of the Department of Therapy, Cardiology and Functional Diagnostics with a course in Nephrology, Central State Medical Academy of the Administrative Dicrectorate of the President of the Russian Federation,; e-mail: zmutovina@mail.ru.
ORCID: 0000-0001-5809-601510:07.
Georgy N. Arbolishvili – Deputy Chief Physician for Anesthesiology and Critical Care, City Clinical Hospital No. 52 of the Moscow Healthcare Department.
Address: 3 Pekhotnaya st., Moscow, 123182; Associate Professor at the Department of Anesthesiology and Critical Care, Faculty of Fundamental Medicine,
Lomonosov Moscow State University; e- mail: geodoc@yandex.ru. ORCID: 0000-0002-2252-3975.
Denis P. Pavlov – Head of the ICU No. 7, City Clinical Hospital No. 52 of the Moscow Healthcare Department. Address: 3 Pekhotnaya st., Moscow, 123182;
e-mail: dr.pavlov@mail.ru. ORCID: 0009-0000-0572-8031.
Daria Yu. Shmeleva – Neurologist of the Rheumatology Department, City Clinical Hospital No. 52 of the Moscow Healthcare Department.
Address: 3 Pekhotnaya st., Moscow, 123182; e-mail: dasha068@icloud.com. ORCID: 0009-0001-8310-2795.
Farid F. Manerov – Resuscitation Physician, ICU No. 2, City Clinical Hospital No. 52 of the Moscow Healthcare Department. Address: 3 Pekhotnaya st.,
Moscow, 123182; e-mail: faridmanerov036@gmail.com. ORCID: 0009-0004-6478-6652.
Maryana A. Lysenko – Dr.Sci. (Med.), Professor, Chief Physician of the City Clinical Hospital No. 52 of the Moscow Healthcare Department.
Address: 3 Pekhotnaya st., Moscow, 123182, Professor at the Department of General Therapy, Pirogov Russian National Research Medical University;
E-mail: gkb52@zdrav.mos.ru. ORCID: 0000-0001-6010-7975.


Similar Articles

Back to Content

Бионика Медиа